Press release
Empagliflozin, Dapagliflozin And Canagliflozin Market Report By Size, Share And Forecast To 2024-2033
Empagliflozin, Dapagliflozin And Canagliflozin Market
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
According to The Business Research Company's, The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.41 billion in 2023 to $9.64 billion in 2024 at a compound annual growth rate (CAGR) of 2.4%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $10.78 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to increasing demand for oral diabetes medications, increasing investments in diabetes research and drug development, increasing healthcare expenditure, rising awareness and diagnosis of pre-diabetes conditions, and increasing focus on combination therapies. Major trends in the forecast period include technological advancements, combination therapies, telehealth, health data analytics, and patient data security.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report
Market Drivers and Trends:
The increasing prevalence of diabetes is expected to propel the growth of the empagliflozin, dapagliflozin, and canagliflozin market going forward. Diabetes presents as a persistent health issue marked by high blood sugar levels stemming from inadequate insulin production or the body's ineffective utilization of insulin. The increasing prevalence of diabetes can be attributed to factors such as sedentary lifestyles, unhealthy dietary habits, genetic predisposition, urbanization, and aging populations, compounded by limited access to healthcare and rising obesity rates worldwide. Empagliflozin, dapagliflozin, and canagliflozin are used in diabetes management to lower blood sugar levels by inhibiting sodium-glucose co-transporter-2 (SGLT2) in the kidneys, promoting the excretion of glucose through urine. For instance, in 2021, according to the International Diabetes Federation, a Belgium-based non-profit organization, the projected number of individuals living with diabetes is expected to increase to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the empagliflozin, dapagliflozin, and canagliflozin market.
Major companies operating in the empagliflozin, dapagliflozin, and canagliflozin markets are focusing on developing innovative products, such as pediatric type-2 diabetes treatment, to address broader patient demographics and expand their market reach in diabetes care. Pediatric Type-2 diabetes treatment involves managing blood sugar levels through lifestyle changes, medications, and sometimes insulin therapy tailored specifically for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. This approval is based on positive results from the T2NOW Phase III clinical trial, one of the most extensive pediatric type-2 diabetes trials to date, which showed that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile of Farxiga in this patient population was consistent with that observed in adults with type-2 diabetes. This approval is an important milestone, as oral treatment options for pediatric type-2 diabetes have been limited, and it underscores AstraZeneca's commitment to delivering innovative treatments across cardiovascular, renal, and metabolic diseases.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
Empagliflozin, Dapagliflozin And Canagliflozin Market 2024 Key Insights:
• The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $10.78 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%.
• Rising Diabetes Prevalence To Drive Growth In The Empagliflozin, Dapagliflozin, And Canagliflozin Market
• Expanding Diabetes Care Through Innovative Pediatric Type-2 Diabetes Treatments
• North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Empagliflozin, Dapagliflozin And Canagliflozin Market Report By Size, Share And Forecast To 2024-2033 here
News-ID: 3722773 • Views: …
More Releases from The Business research company
2025-2034 Wearable Fitness Trackers Market Outlook: Key Drivers, Emerging Challe …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Wearable Fitness Trackers Industry Market Size Be by 2025?
The market for wearable fitness monitoring devices has experienced significant expansion lately, projected to move from a valuation of $51.28 billion in 2024 to $60.04 billion by 2025, reflecting a compound annual growth rate (CAGR) of 17.1%.…
Key Factor Supporting Global Spatial Genomics And Transcriptomics Market Develop …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Spatial Genomics And Transcriptomics Market Size By 2025?
The overall valuation of the spatial genomics and transcriptomics sector has experienced a swift ascent lately, projected to advance from its 2024 benchmark of $1.51 billion to $1.7 billion by 2025, reflecting a compound annual growth rate…
Emerging Trends to Drive Point Of Care Infectious Disease Testing Market Growth …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Point Of Care Infectious Disease Testing Market Size Growth Forecast: What to Expect by 2025?
The market encompassing point-of-care testing for infectious diseases has experienced swift expansion lately, projected to increase its valuation from $4.21 billion at the close of 2024 to $4.78 billion by 2025, reflecting a compound…
Emerging Trends to Reshape the Global Pernicious Anemia Diagnosis And Treatment …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pernicious Anemia Diagnosis And Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market associated with pernicious anemia diagnosis and subsequent therapy has experienced robust expansion over the past few years, projected to advance from a value of $1.42 billion in 2024 to $1.51…
More Releases for Empagliflozin
Global Empagliflozin, Dapagliflozin And Canagliflozin Market Outlook 2025-2034: …
The Empagliflozin, Dapagliflozin And Canagliflozin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Empagliflozin, Dapagliflozin And Canagliflozin Market Size and Projected Growth Rate?
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in…
Empagliflozin Impurity Standards: Ensuring Uncompromised Drug Quality with Preci …
Empagliflozin, a widely prescribed medication for managing Type 2 diabetes, has revolutionized the approach to treatment by enabling better glycemic control and reducing cardiovascular risks. As its demand grows, so does the need for impeccable quality standards to ensure its efficacy and safety for patients worldwide. Integral to achieving this is the availability of well-characterized impurity standards, which form the cornerstone for rigorous quality testing.
To meet these precise requirements, Empagliflozin…
Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-3 …
Product Name:Empagliflozin Intermediate 3
Image: https://www.abnewswire.com/upload/2025/02/244d490e8e67be1fc6fd489f30405e07.jpg
CAS NO.:1279691-36-9
Synonyms:
Empagliflozin N-1;
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol;
Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]Methyl]phenyl]-alpha-D-glucopyranoside;
Related Categories:Empagliflozin intermediates; pharmaceutical raw materials; pharmaceutical intermediates; organic intermediates.
Appearance: White to Off-White solid
Purity: 98%
Application: Empagliflozin intermediates;pharmaceutical intermediate
Supply Ability
Empagliflozin Intermediate3 CAS NO.1279691-36-9 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
If you are interested in Empagliflozin Intermediate3 CAS NO.1279691-36-9, feel freely contact us please, and we will provide…
Empagliflozin, Dapagliflozin And Canagliflozin Market Size, Share Analysis And T …
The new report published by The Business Research Company, titled Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from…
Empagliflozin, Dapagliflozin and Canagliflozin Market Research Report 2023: …
Empagliflozin, Dapagliflozin and Canagliflozin are three main types of SGLT-2 inhibitors.
Global Empagliflozin, Dapagliflozin and Canagliflozin Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the…
Empagliflozin Tablets Market Opportunities and Growth Challenges Report 2022-203 …
Global Empagliflozin Tablets Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis
Empagliflozin Tablets Market Overview
The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global Empagliflozin Tablets Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as well as the…
